Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
Search
The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
Discover your hidden talent with BI Open – the new platform for data science enthusiasts
Discover your hidden talent with BI Open – the new platform for data science enthusiasts. For more talent insights, visit our Careers Page.
Prioritizing mental health and well-being today and every day
Prioritizing Mental Health and Well-being Today and Everyday
New consortium EUbOPEN will provide tools to unlock disease biolog
New consortium EUbOPEN will provide tools to unlock disease biolog
Brazil
Brazil
Dubai
Dubai
Manufacturing & Supply Chain
Manufacturing & Supply Chain
From garbage to garden - Recycling organic waste to contribute to a healthier planet
From garbage to garden - Recycling organic waste to contribute to a healthier planet
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Human Health Partnering
Human Health Partnering
Information Technology
IT
Parasiticides
Parasiticides
Technologies
We are expanding our global network of technology partners. Learn more about partnering with us.
More Health Overview
Working at the intersection of human and animal health, we have unique opportunities to positively impact vulnerable populations.
Mental Health disorders
Mental Health disorders
We’re All In
We’re All In
A grandmother’s empathy offers a safe space for people with mental health conditions
Supporting the Friendship Bench to improve access to mental healthcare.
Vaccines
Vaccines
Animal Health Partnering
Animal Health Partnering
Partnering with Boehringer Ingelheim
Information on partnering with Boehringer Ingelheim including how the company enables new science, partnering interests and key facts on the R&D pipeline.
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates
Metabolic Diseases
CardioMetabolic Disease Research
Animal Health Partnering Interests
Learn about our Partnering Interests and how we can work together to advance innovation in animal health
Oncology & Cancer Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.